Cytek Biosciences, Inc. (CTKB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 80M 160M 240M Q3 '21: 119.7M Q4 '21: 128M Q1 '22: 138.7M Q2 '22: 148.5M Q3 '22: 154.6M Q4 '22: 164M Q1 '23: 166.1M Q2 '23: 175.6M Q3 '23: 183.1M Q4 '23: 193M Q1 '24: 200.8M Q2 '24: 197.7M Q3 '24: 201.2M Q4 '24: 200.5M Q1 '25: 197.1M Q2 '25: 196M Q3 '25: 196.8M Q4 '25: 201.5M Q1 '26: 204.2M Q2 '26: 206.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 40M 80M 120M Q3 '21: 75M Q4 '21: 79.1M Q1 '22: 84.8M Q2 '22: 89.7M Q3 '22: 95.2M Q4 '22: 101M Q1 '23: 101.8M Q2 '23: 105.4M Q3 '23: 105.8M Q4 '23: 109.4M Q1 '24: 111.4M Q2 '24: 108.7M Q3 '24: 110.5M Q4 '24: 111.1M Q1 '25: 108.2M Q2 '25: 106.7M Q3 '25: 105.2M Q4 '25: 104.5M Q1 '26: 105.6M Q2 '26: 110M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income TTM

-60M -40M -20M 0 20M 40M 60M Q3 '21: 15.7M Q4 '21: 9.2M Q1 '22: 5.7M Q2 '22: 966K Q3 '22: -571K Q4 '22: -1.8M Q1 '23: -11.6M Q2 '23: -19.8M Q3 '23: -27.6M Q4 '23: -27.8M Q1 '24: -26.4M Q2 '24: -25.8M Q3 '24: -23.6M Q4 '24: -20.5M Q1 '25: -24.8M Q2 '25: -26.9M Q3 '25: -31.8M Q4 '25: -40.4M Q1 '26: -43.9M Q2 '26: -44.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-90M -60M -30M 0 30M 60M 90M Q3 '21: 9.8M Q4 '21: 4.2M Q1 '22: 1.9M Q2 '22: -1.4M Q3 '22: -1.2M Q4 '22: 2.3M Q1 '23: -2.4M Q2 '23: -6M Q3 '23: -14.1M Q4 '23: -12.1M Q1 '24: -11.5M Q2 '24: -17.6M Q3 '24: -10.2M Q4 '24: -6M Q1 '25: -11.3M Q2 '25: -6.4M Q3 '25: -12.8M Q4 '25: -66.5M Q1 '26: -74M Q2 '26: -80.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 35M 70M 105M Q3 '21: 44.7M Q4 '21: 48.8M Q1 '22: 53.9M Q2 '22: 58.8M Q3 '22: 59.4M Q4 '22: 63.1M Q1 '23: 64.2M Q2 '23: 70.2M Q3 '23: 77.4M Q4 '23: 83.6M Q1 '24: 89.4M Q2 '24: 89M Q3 '24: 90.7M Q4 '24: 89.3M Q1 '25: 88.8M Q2 '25: 89.4M Q3 '25: 91.6M Q4 '25: 97M Q1 '26: 98.6M Q2 '26: 96.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-15M 0 15M 30M 45M Q3 '21: 10.8M Q4 '21: 4.6M Q1 '22: 1.2M Q2 '22: -4.3M Q3 '22: -13M Q4 '22: -12.2M Q1 '23: -7.9M Q2 '23: -1.3M Q3 '23: 2M Q4 '23: 5.3M Q1 '24: 6.4M Q2 '24: 15.4M Q3 '24: 32.9M Q4 '24: 25.4M Q1 '25: 21.3M Q2 '25: 15.2M Q3 '25: -1.9M Q4 '25: -4.7M Q1 '26: -7.3M Q2 '26: -6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-30M -20M -10M 0 10M 20M 30M Q3 '21: 7.6M Q4 '21: 266K Q1 '22: -3.4M Q2 '22: -9M Q3 '22: -17.5M Q4 '22: -22M Q1 '23: -17.4M Q2 '23: -10.8M Q3 '23: -7.7M Q4 '23: 633K Q1 '24: 1.7M Q2 '24: 11M Q3 '24: 28.8M Q4 '24: 21.9M Q1 '25: 17.5M Q2 '25: 10.9M Q3 '25: -5.9M Q4 '25: -8.8M Q1 '26: -12.7M Q2 '26: -12.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '20: 31.1M Q3 '20: 31.1M Q1 '21: 35.8M Q2 '21: 36.2M Q3 '21: 113.6M Q1 '22: 133.9M Q2 '22: 134.4M Q3 '22: 138.7M Q1 '23: 135.5M Q2 '23: 135.9M Q3 '23: 136.2M Q1 '24: 130.9M Q2 '24: 131.4M Q3 '24: 132.8M Q1 '25: 128.3M Q2 '25: 126.9M Q3 '25: 127.5M Q1 '26: 128.7M Q2 '26: 129.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 0.01 0.03 0.04 Q3 '21: 0.01 Q4 '21: 0.00 Q1 '22: 0.02 Q2 '22: 0.02 Q3 '22: 0.01 Q4 '22: 0.04 Q3 '21 Q4 '21 Q1 '22 Q2 '22 Q3 '22 Q4 '22

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.